Magnetic porous carbons derived from iron-based metal-organic framework loaded with glucose for effective extraction of synthetic organic dyes in drinks.

The conversion of metal-organic frameworks (MOFs) to porous carbon has attracted extensive attention for developing multifunctional adsorbent materials. Herein, we demonstrated a facile method to prepare magnetic porous carbon via calcinating MIL-101(Fe) precursor loaded with glucose at 700 °C in an N2 atmosphere. The obtained magnetic porous carbon (MPCG) contained plenty of oxygen-containing functional groups and exhibited an enlarged specific surface area (177.7 m2/g) compared with its precursor (41.2 m2/g). In addition, MPCG can be easily separated from the matrix by a magnet. Benefitting from these advantages, the magnetic porous carbon exhibited high affinity toward four synthetic organic dyes (amaranth, ponceau 4R, sunset yellow, and lemon yellow) in an aqueous solution. Moreover, the adsorbent can be applied to quantitatively detect synthetic organic dyes in drinks coupled with chromatography. A new magnetic solid-phase extraction method for dye analysis yielded reasonable linearity (r â–¡ 0.99), low limits of detection (0.047-0.076 µg/L), and good precision within the analyte concentration range of 0.25-50 µg/L.

The impact of obesity on adipocyte-derived extracellular vesicles.

Recently, the emerging roles of adipocyte-derived extracellular vesicles (EVs) linking obesity and its comorbidities have been recognized. In obese subjects, adipocytes are having hypertrophic growth and are under stressed. The dysfunction adipocytes dysregulate the assembly of the biological components in the EVs including exosomes. This article critically reviews the current findings on the impact of obesity on the exosomal cargo contents that induce the pathophysiological changes. Besides, this review also summarizes the understanding on how obesity affects the biogenesis of adipocyte-derived exosomes and the exosome secretion. Furthermore, the differences of the exosomal contents in different adipose depots, and the impact of obesity on the exosomes that are derived from the stromal vascular fraction such as the adipose tissue macrophages and adipocyte-derived stem cells will also be discussed. The current development and potential application of exosome-based therapy will be summarized. This review provides crucial information for the design of novel exosome-based therapy for the treatment of obesity and its comorbidities.

Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis.

Hepatocellular carcinoma (HCC) is difficult to treat, and is the second leading cause of cancer-related death worldwide. This study aimed to examine whether combination of wogonin and artesunate exhibits synergistic anti-HCC effect. Our data show that the combination treatment exhibits synergistic effect in reducing HCC cell viability by increasing apoptosis as indicated by the elevated cleavage of caspase 8, 3 and PARP. Interestingly, PCR array and the subsequent studies indicate that the combination treatment significantly increases the expression of DNA-damage-inducible, alpha (GADD45A), tumor necrosis factor (TNFα) and TNF receptor-associated factor 3 (TRAF3). Knockdown of GADD45A, TNFα or TRAF3 abolishes the combination treatment-enhanced apoptosis and the synergistic effect in reducing HCC cell viability. In the HCC-bearing xenograft mouse models, although the combination treatment increases the activity of NFκB in the tumor tissues, it exhibits a more potent anti-HCC effect than the mono-treatment, which may due to the enhanced apoptosis as indicated by the increased expression of GADD45A, TNFα, TRAF3 and apoptotic markers. Our study clearly demonstrates that the combination of artesunate and wogonin exhibits synergistic anti-HCC effect, and support the further development of this combination as alternative therapeutics for HCC management.